Drugs giant GSK has seen shares come under pressure as falling vaccine sales overshadowed a better-than-forecast rise in quarterly profits.
The British pharmaceutical firm revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles jab Shingrix and Arexvy shot for the respiratory virus RSV.